Organon (OGN) Other financing activities (2020 - 2021)
Organon (OGN) posted quarterly Other financing activities of -$112.0 million for Q2 2021, down 202.75% year-over-year from $109.0 million in Q2 2020, and up 54.1% on a QoQ basis from -$244.0 million in Q1 2021.
Organon (OGN) Other financing activities (2020 - 2021) Analysis & Trends
Organon has reported Other financing activities for 2 years, with the latest figure at -$112.0 million in Q2 2021.
- Other financing activities for Q2 2021 came in at -$112.0 million, down 202.75% year-over-year; the trailing twelve-month figure through Mar 2022 was -$112.0 million (up 77.0% YoY), and the FY2021 annual result was -$356.0 million, down 132.68% from the prior year.
- Other financing activities advanced to -$112.0 million in Q2 2021, from -$244.0 million in the prior quarter.
- Over five years, Other financing activities peaked at $109.0 million in Q2 2020 and troughed at -$324.0 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -112.00 Mn |
| Jun 30, 2021 | -112.00 Mn |
| Mar 31, 2021 | -244.00 Mn |
| Mar 31, 2021 | -244.00 Mn |
| Dec 31, 2020 | -324.00 Mn |
| Dec 31, 2020 | -324.00 Mn |
| Sep 30, 2020 | -28.00 Mn |
| Sep 30, 2020 | -28.00 Mn |
| Jun 30, 2020 | 109.00 Mn |
| Jun 30, 2020 | 109.00 Mn |
| Mar 31, 2020 | 90.00 Mn |
| Mar 31, 2020 | 90.00 Mn |